Palbociclib vs Tibremciclib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline
Palbociclib · Ibrance
Marketed by Pfizer
NCT01740427 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.
Next expected readout: November 2026 · NCT02605486 (registry estimate)
Reported efficacy
Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) (met)
Result source: NCT02297438
Tibremciclib · Kangmeina
Marketed by Betta Pharmaceuticals Co.
NCT05433480 · Phase 3 · status unknown
This randomised, quadruple-blind, placebo-controlled trial in 274 women with HR-positive, HER2-negative advanced breast cancer reported median progression-free survival of 16.5 months with tibremciclib plus fulvestrant against 5.6 months with placebo plus fulvestrant, a hard clinical endpoint.
Result from the peer-reviewed publication (JAMA Oncology 2025); the registry has no posted results and its status is not updated.
Reported efficacy
Investigator-assessed PFS (up to 3 years): Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001 (met)
Result source: NCT05433480
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Palbociclib | Tibremciclib |
|---|---|---|
| PFS, median | 24.8 vs 14.5+10.3 vs placeboNCT0174042720 other results
| —Not reported |
| OS, median | 53.9 vs 51.2+2.7 vs placeboNCT0174042714 other results
| —Not reported |
| ORR | 46.4% vs 38.3%+8.1 vs placeboNCT0174042715 other results
| —Not reported |
| Clinical benefit rate | 85.8% vs 71.2%+14.6 vs placeboNCT0174042710 other results
| —Not reported |
PFS, median
- Palbociclib
- 24.8 vs 14.5+10.3 vs placeboNCT01740427
20 other results
- 21.5 vs 13.9 NCT02297438
- 9.2 vs 3.8 NCT01942135
- 7.3 vs 10 NCT02028507
- 7.5 vs 10 NCT02028507
- 21.6 vs 16.4 NCT02297438
- 8 vs 10.6 NCT02028507
- 20.2 vs 10.2 NCT00721409
- 26.1 vs 10.2 NCT00721409
- 18.1 vs 10.2 NCT00721409
- 11.3 NCT02630693
- 9.3 NCT02630693
- 9.1 NCT02668666
- 16.9 NCT03530696
- 8.3 NCT03530696
- 4.1 NCT02913430
- 9.4 NCT02384239
- 6.5 NCT02384239
- 29.4 NCT03633331
- 30.4 NCT03691493
- 18.6 NCT02499146
- Tibremciclib
- —Not reported
OS, median
- Palbociclib
- 53.9 vs 51.2+2.7 vs placeboNCT01740427
14 other results
- 53.8 vs 49.8 NCT01740427
- 51.7 vs 51.5 NCT02297438
- 50.3 vs 49.7 NCT02297438
- 34.9 vs 28 NCT01942135
- 33.7 vs 32 NCT02028507
- 37.5 vs 34.5 NCT00721409
- 37.5 vs 34.5 NCT00721409
- 35.1 vs 34.5 NCT00721409
- 21.4 NCT02630693
- 20.7 NCT02630693
- 35.6 NCT03633331
- 35.1 NCT03530696
- 37.9 NCT03691493
- 18.8 NCT02913430
- Tibremciclib
- —Not reported
ORR
- Palbociclib
- 46.4% vs 38.3%+8.1 vs placeboNCT01740427
15 other results
- 37.3% vs 31.6% NCT02297438
- 43.4% vs 38% NCT02297438
- 40.2% vs 33.9% NCT02297438
- 52.3% vs 43.5% NCT02297438
- 21% vs 8.6% NCT01942135
- 42.9% vs 33.3% NCT00721409
- 44.1% vs 33.3% NCT00721409
- 42% vs 33.3% NCT00721409
- 55.4% vs 39.4% NCT00721409
- 55.6% vs 39.4% NCT00721409
- 55.3% vs 39.4% NCT00721409
- 47.6% NCT01684215
- 30% NCT02668666
- 33.3% NCT00721409
- 19.2% NCT02499146
- Tibremciclib
- —Not reported
Clinical benefit rate
- Palbociclib
- 85.8% vs 71.2%+14.6 vs placeboNCT01740427
10 other results
- 79.3% vs 80.1% NCT02297438
- 77.9% vs 79.6% NCT02297438
- 76.9% vs 73.1% NCT02297438
- 78.1% vs 71.8% NCT02297438
- 66.3% vs 39.7% NCT01942135
- 81% vs 58% NCT00721409
- 76.5% vs 58% NCT00721409
- 84% vs 58% NCT00721409
- 64% NCT02668666
- 83.3% NCT00721409
- Tibremciclib
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Palbociclib: 4 of 4 rows · Tibremciclib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Palbociclib |
|---|---|
| Dropout rate | n/a: no completion milestonea NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 55 more resultsn/a: no completion milestone NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestone NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 69.1%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 34%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02600923 · Phase 3 · registry result, not featured evidence · combination 0% NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 1.1% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 87.5% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 1.1%125mg NCT02630693 · Phase 2 · registry result, not featured evidence 0%100mg NCT02630693 · Phase 2 · registry result, not featured evidence 0% NCT02668666 · Phase 2 · registry result, not featured evidence 1.4% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 1.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02536742 · Phase 2 · registry result, not featured evidence 12.5%Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence 2.6%T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination 2.8% NCT03691493 · Phase 2 · registry result, not featured evidence · combination 0%125mg NCT02384239 · Phase 2 · registry result, not featured evidence 0%100mg NCT02384239 · Phase 2 · registry result, not featured evidence n/a: no completion milestone125 mg NCT01684215 · Phase 2 · registry result, not featured evidence —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT01684215 · Phase 2 · registry result, not featured evidence —Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 100%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 97.6%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy n/a: no completion milestone25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone NCT02499146 · Phase 1 · registry result, not featured evidence · combination 0%Fulvestrant + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination 0%Tamoxifen + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination —8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 7.2%a NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 55 more results8.9% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 — NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 3.9%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 2%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 5.2%Cohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 2%Cohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination — NCT03633331 · Phase 2 · registry result, not featured evidence · combination — NCT04224272 · Phase 2 · registry result, not featured evidence · combination —125mg NCT02630693 · Phase 2 · registry result, not featured evidence —100mg NCT02630693 · Phase 2 · registry result, not featured evidence — NCT02668666 · Phase 2 · registry result, not featured evidence — NCT03644186 · Phase 2 · registry result, not featured evidence · combination — NCT03007979 · Phase 2 · registry result, not featured evidence · combination — NCT02536742 · Phase 2 · registry result, not featured evidence —Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence —T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination — NCT03691493 · Phase 2 · registry result, not featured evidence · combination —125mg NCT02384239 · Phase 2 · registry result, not featured evidence —100mg NCT02384239 · Phase 2 · registry result, not featured evidence 0%125 mg NCT01684215 · Phase 2 · registry result, not featured evidence —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination —125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 16.7%100 mg NCT01684215 · Phase 2 · registry result, not featured evidence —Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 0%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 15.5%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination —300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy —25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination —125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 11.5% NCT02499146 · Phase 1 · registry result, not featured evidence · combination —Fulvestrant + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination —Tamoxifen + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination —8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 50%8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 33.3%6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 0%5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 28.2%a NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 55 more results22.6% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 20.2% NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 29.6%Palbociclib+Letrozole Australia Co NCT02679755 · Phase 4 · registry result, not featured evidence · combination 18%Palbociclib+Letrozole India Cohort NCT02679755 · Phase 4 · registry result, not featured evidence · combination 22.7%Cohort 1: Palbociclib Plus Exemest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 14.1%Cohort 2: Palbociclib Plus Fulvest NCT02028507 · Phase 3 · registry result, not featured evidence · combination 24.6% NCT02600923 · Phase 3 · registry result, not featured evidence · combination — NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination 38% NCT03633331 · Phase 2 · registry result, not featured evidence · combination 15.7% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 13.5%125mg NCT02630693 · Phase 2 · registry result, not featured evidence 10%100mg NCT02630693 · Phase 2 · registry result, not featured evidence 32.7% NCT02668666 · Phase 2 · registry result, not featured evidence 54.2% NCT03644186 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT03007979 · Phase 2 · registry result, not featured evidence · combination 73% NCT02536742 · Phase 2 · registry result, not featured evidence 21.4%Single Agent T-DM1 NCT03530696 · Phase 2 · registry result, not featured evidence 21.1%T-DM1 With Palbociclib NCT03530696 · Phase 2 · registry result, not featured evidence · combination — NCT03691493 · Phase 2 · registry result, not featured evidence · combination 5.9%125mg NCT02384239 · Phase 2 · registry result, not featured evidence 13.9%100mg NCT02384239 · Phase 2 · registry result, not featured evidence 0%125 mg NCT01684215 · Phase 2 · registry result, not featured evidence 9.5%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 33.3%125 mg + 2.5 mg NCT01684215 · Phase 2 · registry result, not featured evidence · combination 0%100 mg NCT01684215 · Phase 2 · registry result, not featured evidence 30.3%Ph2P1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 24%Ph2P2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 16.7%Phase 1 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 26.5%Phase 2 (Palbociclib + Letrozole) NCT00721409 · Phase 2 · registry result, not featured evidence · combination 20%300 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 33.3%150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 0%150 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 13.3%150 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 16.7%100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 33.3%100 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 16.7%75 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%75 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 0%50 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 11.1%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 0%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 12%50 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 20%25 mg BID NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 40%25 mg QD NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 100%125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 83.3%100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 87.5%100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 15.4% NCT02499146 · Phase 1 · registry result, not featured evidence · combination 40%Fulvestrant + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination 0%Tamoxifen + Palbociclib NCT02913430 · Phase 1 · registry result, not featured evidence · combination 25%8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —8 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 16.7%6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —6 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination 33.3%5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination —5 mg NCT03238196 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a neutropenia 69.4% (placebo 3.6%) arthralgia 42.1% (placebo 40.1%) fatigue 41.2% (placebo 29.3%) NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 49 more resultsneutropenia 67% fatigue 43.8% nausea 36.5% NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutrophil count decreased 66.7% (placebo 11.1%) white blood cell count decreased 64.3% (placebo 9.9%) neutropenia 44.6% (placebo 7%) NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 neutropenia 72.4% fatigue 65.1% nausea 37.5% NCT02679755 · Phase 4 · registry result, not featured evidence · combination neutropenia 57% anaemia 22% alopecia 17% NCT02679755 · Phase 4 · registry result, not featured evidence · combination neutrophil count decreased 62.7% fatigue 55.3% hypertension 34% NCT02028507 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 63.1% fatigue 51% hypertension 36.9% NCT02028507 · Phase 3 · registry result, not featured evidence · combination neutropenia 70% leukopenia 34.6% anaemia 33.8% NCT02600923 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 92.4% white blood cell decreased 87% fatigue 84.8% NCT03633331 · Phase 2 · registry result, not featured evidence · combination diarrhoea 92.2% nausea 52.9% stomatitis 41.2% NCT04224272 · Phase 2 · registry result, not featured evidence · combination 125mg fatigue 82% nausea 53.9% back pain 46.1% NCT02630693 · Phase 2 · registry result, not featured evidence 100mg fatigue 85.6% nausea 52.2% insomnia 48.9% NCT02630693 · Phase 2 · registry result, not featured evidence neutrophil count decreased 71.4% fatigue 65.3% white blood cell decreased 65.3% NCT02668666 · Phase 2 · registry result, not featured evidence diarrhea 65.3% anemia 48.6% platelet count decreased 38.9% NCT03644186 · Phase 2 · registry result, not featured evidence · combination white blood cell count decreased 96.3% neutrophil count decreased 87% anemia 79.6% NCT03007979 · Phase 2 · registry result, not featured evidence · combination nausea 57.1% aspartate aminotransferase increased 50% fatigue 50% NCT03530696 · Phase 2 · registry result, not featured evidence neutrophil count decreased 84.2% platelet count decreased 76.3% white blood cell count decreased 76.3% NCT03530696 · Phase 2 · registry result, not featured evidence · combination 125mg neutrophil count decreased 26.5% hypertension 0% NCT02384239 · Phase 2 · registry result, not featured evidence 100mg neutrophil count decreased 13.9% hypertension 5.6% NCT02384239 · Phase 2 · registry result, not featured evidence 125 mg white blood cell count decreased 83.3% diarrhoea 66.7% neutrophil count decreased 66.7% NCT01684215 · Phase 2 · registry result, not featured evidence 125 mg + 2.5 mg neutrophil count decreased 81% stomatitis 76.2% white blood cell count decreased 71.4% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 125 mg + 2.5 mg neutrophil count decreased 100% white blood cell count decreased 100% diarrhoea 66.7% NCT01684215 · Phase 2 · registry result, not featured evidence · combination 100 mg neutrophil count decreased 83.3% white blood cell count decreased 66.7% aspartate aminotransferase increased 33.3% NCT01684215 · Phase 2 · registry result, not featured evidence neutropenia 78.8% leukopenia 48.5% fatigue 42.4% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 72% fatigue 40% leukopenia 40% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 91.7% fatigue 83.3% leukopenia 66.7% NCT00721409 · Phase 2 · registry result, not featured evidence · combination neutropenia 74.7% leukopenia 43.4% fatigue 41% NCT00721409 · Phase 2 · registry result, not featured evidence · combination 300 mg QD nausea 40% fatigue 30% headache 30% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 150 mg QD neutrophil count decreased 100% anaemia 66.7% fatigue 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 150 mg BID abdominal pain 66.7% ggt increased 66.7% nausea 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 150 mg QD nausea 40% headache 26.7% hypertension 26.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 100 mg QD white blood cell count decreased 91.7% neutrophil count decreased 58.3% anaemia 41.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 100 mg QD abdominal pain upper 33.3% arthralgia 33.3% back pain 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 75 mg BID arthralgia 33.3% fall 33.3% fatigue 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 75 mg QD hypophosphataemia 66.7% blood alkaline phosphatase increased 33.3% breast pain 33.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 50 mg BID alt increased 50% anaemia 50% cough 50% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 50 mg QD neutrophil count decreased 77.8% white blood cell count decreased 77.8% anaemia 66.7% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 50 mg QD fatigue 25% ggt increased 18.8% arthralgia 12.5% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 50 mg QD ggt increased 14.7% covid-19 10.7% ast increased 9.3% NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy 25 mg BID nausea 60% neutrophil count decreased 60% white blood cell count decreased 60% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 25 mg QD neutrophil count decreased 80% white blood cell count decreased 70% anaemia 50% NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination 125mg mucositis oral 100% neutrophil count decreased 100% platelet count decreased 100% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 100mg mucositis oral 100% neutrophil count decreased 83.3% fatigue 50% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 100mg mucositis oral 96.9% neutrophil count decreased 87.5% fatigue 65.6% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination neutrophil count decreased 61.5% platelet count decreased 57.7% white blood cell count decreased 57.7% NCT02499146 · Phase 1 · registry result, not featured evidence · combination dyspnea 60% neutrophil count decreased 60% skin and subcutaneous tissue disorders - other 60% NCT02913430 · Phase 1 · registry result, not featured evidence · combination blood and lymphatic system disorders - other 50% hypertension 50% neutrophil count decreased 50% NCT02913430 · Phase 1 · registry result, not featured evidence · combination 8 mg diarrhea 75% oral mucositis 75% dry skin 50% NCT03238196 · Phase 1 · registry result, not featured evidence · combination 6 mg fatigue 83.3% oral mucositis 83.3% dry mouth 66.7% NCT03238196 · Phase 1 · registry result, not featured evidence · combination 5 mg anemia 100% constipation 100% dry skin 100% NCT03238196 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 53 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Palbociclib
show 9 more results
show 11 more results
show 7 more results
show 8 more results
show 8 more results
show 1 more result
show 1 more result
show 3 more results
+ 77 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Palbociclib's landscape · Tibremciclib's landscape